Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development...

Por Koutsilieris, M., Mitsiades, C., Sourla, A.
Publicado em 2000

A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice

Por Hu, Y, Zheng, M, Gali, R, Tian, Z, Topal Görgün, G, Munshi, N C, Mitsiades, C S, Anderson, K C
Publicado em 2013

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Por Siegel, D S, Richardson, P, Dimopoulos, M, Moreau, P, Mitsiades, C, Weber, D, Houp, J, Gause, C, Vuocolo, S, Eid, J, Graef, T, Anderson, K C
Publicado em 2014

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Por Siegel, D S, Richardson, P, Dimopoulos, M, Moreau, P, Mitsiades, C, Weber, D, Houp, J, Gause, C, Vuocolo, S, Eid, J, Graef, T, Anderson, K C
Publicado em 2014

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo

Por Shammas, MA, Koley, H, Bertheau, RC, Neri, P, Fulciniti, M, Tassone, P, Blotta, S, Protopopov, A, Mitsiades, C, Batchu, RB, Anderson, KC, Chin, A, Gryaznov, S, Munshi, NC
Publicado em 2008